Evidence map›Paper›PMID 38247203›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

A Pro-Regenerative Supramolecular Prodrug Protects Against and Repairs Colon Damage in Experimental Colitis.

Kelsey G DeFrates, Elaine Tong, Jing Cheng, Ellen Heber-Katz, Phillip B Messersmith

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. An orally deliverable CoMaterials today. Bio · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kelsey G DeFratesDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0002-3485-2477
Elaine TongDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, 94720, USA.
Jing ChengDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, 94720, USA.
Ellen Heber-KatzLankenau Institute for Medical Research, Wynnewood, PA, 19096, USA.
Phillip B MessersmithDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0002-1197-333X
University of California, Berkeley · USLankenau Institute for Medical Research · USLawrence Berkeley National Laboratory · US

Funding

Regenerative wound healing via inflammation-modulating biomaterialsR01DE021104 · NIDCR · WISTAR INSTITUTE · PI Georgios Hajishengallis, Ellen s. Heber-Katz · 2011 to 2026
$8.5M
NIDCR NIH HHS R01 DE021104NIH HHS R01DE021104
6 · The paper itself

Abstract

Structural repair of the intestinal epithelium is strongly correlated with disease remission in inflammatory bowel disease (IBD); however, ulcer healing is not addressed by existing therapies. To address this need, this study reports the use of a small molecule prolyl hydroxylase (PHD) inhibitor (DPCA) to upregulate hypoxia-inducible factor one-alpha (HIF-1α) and induce mammalian regeneration. Sustained delivery of DPCA is achieved through subcutaneous injections of a supramolecular hydrogel, formed through the self-assembly of PEG-DPCA conjugates. Pre-treatment of mice with PEG-DPCA is shown to protect mice from epithelial erosion and symptoms of dextran sodium sulfate (DSS)-induced colitis. Surprisingly, a single subcutaneous dose of PEG-DPCA, administered after disease onset, leads to accelerated weight gain and complete restoration of healthy tissue architecture in colitic mice. Rapid DPCA-induced restoration of the intestinal barrier is likely orchestrated by increased expression of HIF-1α and associated targets leading to an epithelial-to-mesenchymal transition. Further investigation of DPCA as a potential adjunctive or stand-alone restorative treatment to combat active IBD is warranted.

Indexed as

ColitisInflammatory Bowel DiseasesAnimalsDisease Models, AnimalIntestinal MucosaMammalsMiceHIF‐1αinflammatory bowel diseaseprolyl hydroxylase inhibitorregeneration

Identifiers

PMID38247203
PMCPMC10987129
OpenAlexW4391107982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.